GIMEMA Foundation is an academic, independent, non-profit organization under Italian law, with no direct government subsidy.
Our revenue comes from grants from institutional, corporate, and private donors and fees charged for studies conducted with partners or services to the haemato-oncology community that enables us to fulfil our mission and vision.
Clinical studies evaluating new drugs for potential registration, or testing therapeutic agents, are conducted also with the contributions from commercial organizations.
This funding is subject to GIMEMA strict principles of independence.
The chart shows the total income of GIMEMA and its source:
Chart
EU projects
The European Union supports projects with great public health value, providing funding that is not otherwise available. Over the years, GIMEMA has participated in several projects funded by the European Commission in various haematological fields.
Funding from Industry
Listed below are the companies currently involved in GIMEMA clinical trials.
- AbbVie
- Amgen
- Argenx
- AstraZeneca
- Beigene
- BMS
- Gilead
- Grifols
- Incyte
- Janssen
- Novartis
- Pfizer
- Roche
- StemLine
- Teva
- Sanofi
Public Foundations and Grantors
- AIL local sections
- AIFA grant fo indipendent research
GIMEMA is grateful to all its supporters including many private individuals who over the years have offered their contributions so that we can ensure therapeutic progress for all cancer patients.